Markets nervous ahead of Inauguration Day

Published 20-JAN-2017 14:32 P.M.


2 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.

Click Here to View Latest Articles

While there weren’t any major falls in market indices or commodities overnight, most trended downwards and there was a sense of nervous scepticism ahead of Inauguration Day, reflecting a fear of the unknown rather than the clinical dissection of information that normally drives markets.

Even well received commentary from European Central Bank President, Mario Draghi which pointed to a continuation of quantitative easing in 2017 failed to spark confidence in that region.

The FTSE 100 was down 0.5% while the Dax finished relatively flat after early gains that occurred on the back of Draghi’s address. The Paris CAC 40 also finished in negative territory, shedding 0.2%.

In the US it was a slow but sustained slide on the Dow as it came off approximately 70 points or 0.4%. The NASDAQ also finished 0.3% lower.

While the oil price rallied strongly to hit an intraday high of US$51.87, it also pulled back to close at US$51.41, a gain of 0.6%, which is some respite after a difficult week.

Gold was relatively unmoved, indicating that investors are unsure whether safe haven investing is appropriate.

Elsewhere in commodity markets, there was little movement in the iron ore price and all base metal prices finished in negative territory with nickel the hardest hit.

It fell from the previous day’s close of approximately US$4.57 to US$4.45, representing a decline of 2.6%.

This could heighten already negative sentiment, as most stocks exposed to nickel have experienced sharp falls in the last week following Indonesia’s decision to recommence exporting nickel concentrate rather than processing it in its own smelters.

The Australian dollar was relatively unmoved against the US dollar and is fetching US$0.756.

It should be noted that broker projections and price targets are only estimates and may not be met. Also, historical data in terms of earnings performance and/or share trading patterns should not be used as the basis for an investment as they may or may not be replicated. Those considering this stock should seek independent financial advice.

General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.


Discover Small Cap
Biotech Stocks

Join thousands of other Investors following our stock commentary for Free